Monoclonal Antibody Infusions in LTCFs
Monoclonal antibody (mAb) therapy has been developed to treat viral infections including COVID-19. Treatments have been approved for patients with COVID-19 who are at risk of progression to severe disease. We wanted to share news about an upcoming webinar explaining more about mAb treatments and a new initiative to bring this therapy into LTCFs.
AMDA Webinar
AMDA, the Society for Post-Acute and Long Term Care Medicine, is sponsoring a March 4 webinar on mAb treatments. Learn more about this promising treatment for your residents with COVID-19. Advance registration required.
March 4, 2021 | 6:00 pm
Long-Term Care Infusion Support Activity
AHCA/NCAL has announced it is partnering with a coalition of other national associations to help connect Medical Reserve Corps (MRC) volunteers with resources for mAb infusion in LTCFs. The initiative is intended to create a pathway that facilitates the use of trained volunteers from local MRC units to support infusion of potentially life-saving mAb therapies. Learn more about the Long-Term Care Infusion Support Activity.